A chronic infection caused by Mycobacterium tuberculosis complex. It commonly affects lungs but can affect any organ (lymph nodes, bones, meninges, abdomen, kidney).
For more information on the management of TB see:
- Manual of the National TB/Leprosy Programme (NTLP) in Uganda 3rd Edition, 2016
- TB Control & Community-based DOTS as an Essential Component of District Health Service
- TB Desk Aide
Cause
- Mycobacterium tuberculosis complex (e.g. tuberculosis, bovis, M. africanum and M. Microti)
- Transmission by droplet inhalation (cough from a patient with open pulmonary TB); can also be through drinking unpasteurised milk, especially M.bovis
Clinical features
General symptoms
- Fevers especially in the evening, excessive night sweats
- Weight loss and loss of appetite
Pulmonary TB
- Chronic cough of >2 weeks (however, in HIV settings, cough of any duration)
- Chest pain, purulent sputum occasionally blood-stained, shortness of breath
Extrapulmonary TB
- Lymphnode TB: Localized enlargement of lymph nodes depending on the site affected (commonly neck)
- Pleural or pericardial effusion
- Abdominal TB: ascites and abdominal pain
- TB meningitis: subacute meningitis (headache, alteration of consciousness)
- Bone or joint TB: swelling and deformity
Complications
- Massive haemoptysis - coughing up >250 mL blood per episode
- Spontaneous pneumothorax and pleural effusion
- TB pericarditis, TB meningitis, TB peritonitis
- Bone TB: can be TB spine with gibbus, TB joints with deformity
- Respiratory failure
TB Case Definitions
CASE DEFINITION |
DESCRIPTION |
Presumptive TB patient |
Any patient who presents with symptoms and signs suggestive of TB (previously called a TB suspect) |
Bacteriologically confirmed TB patient |
Patient in whom biological specimen is positive by smear microscopy, culture, Xpert MTB/RIF. All such cases should be notified (registered in the unit TB register) |
Clinically diagnosed TB patient |
Patient who does not fulfil the criteria for bacteriological confirmation but has been diagnosed with active TB by a clinician or other medical practitioner on the basis of clinical symptoms and other investigations |
Classification of TB Infection
CRITERIA |
CLASSIFICATION |
Site of the disease |
Pulmonary TB: bacteriologically confirmed or clinically diagnosed case, affecting lung parechyma or tracheobronchial tree. Isolated TB pleural effusion and mediastinal lymphadenopathy without lung tissue involvement is considered extrapulmonary TB |
Extrapulmonary TB: any other case of TB. If the patient has pulmonary and extrapulmonary involvement, he/ she will be classified as pulmonary |
|
History of treatment |
New: no previous TB treatment (or treatment less < 1 month) |
Relapse: patient who completed a previous course of treatment, was declared cured or treatment completed, and is now diagnosed with a recurrent episode of TB |
|
Treatment after failure: those who have previously been treated for TB and whose treatment failed at the end of their most recent course of treatment |
|
Treatment after loss to follow- up patients: have previously been treated for TB and were declared lost to follow-up at the end of their most recent course of treatment. (These were previously known as treatment after default patients) |
|
Other previously treated patients are those who have previously been treated for TB but whose Outcome after their most recent course of treatment is unknown or undocumented |
|
HIV status |
Positive: patients who tested HIV positive at time of diagnosis or already enrolled in HIV care |
Negative: patients who tested negative at the moment of diagnosis |
|
Unknown: If testing is then performed at any moment during treatment, patient should be re classified |
|
Drug resistance (based on drug susceptibility Tests) |
Rifampicin resistant: any case of rifampicin resistance (isolated or in combination with other resistance) (RR-TB) |
Monoresistant: resistant to only one first line anti-TB drug |
|
Poly drug resistant: resistant to more than one first line anti TB other than both rifampicin and isoniazid |
|
Multi drug resistant: resistant to rifampicin and isoniazid (MDR –TB) |
|
Extensive drug resistance: resistant to rifampicin, isoniazid and any fluoroquinolone and at least one of the 3 second line injectable drugs (capreomycin, kanamycin, amikacin) (XDR-TB). |
Differential Diagnosis
- Histoplasma pneumonia, trypanosomiasis, brucellosis
- HIV/AIDS
- Malignancy
- COPD, asthma, bronchiectasis, emphysema etc.
- Fungal infection of the lungs e.g. Aspergillosis
Investigations for TB Infection
- Sputum smear microscopy for AAFBs (ZN stain)
- one spot and one early morning sample. If one is positive, it is diagnostic for pulmonary TB. This test is widely available in many facilities with a laboratory.
- Sputum samples for children can be collected by inducing sputum using sputum induction kits
- GeneXpert MTB/Rif: automated DNA test on body samples (sputum, lymphonodes tissue, pleural fluid, CSF etc) which can diagnose pulmonary TB and determine susceptibility to Rifampicin. It is superior to microscopy.
- Genexpert MTB/Rif should be used as initial test for TB diagnosis among all presumptive TB
- In facilities with no GeneXpert machines on site, microscopy can be used for TB diagnosis except in priority (risk) groups like: HIV positive patients, children <14 years, pregnant and breastfeeding mothers, health workers, contacts with drug resistant TB patients, re- treatment cases, patients from prisons or refugee camps, diabetics
- For these priority groups, take a sputum sample and send to a facility with a geneXpert machine through the sample referral system (hub system).
- Other investigations
- Can be used for sputum and GeneXpert negative patients or in case of extrapulmonary TB according to clinical judgement (Chest and spine X ray, abdominal ultrasound, biopsies etc)
- Sputum culture and Drug susceptibility test: is a confirmatory test for TB and also provides resistance pattern to TB medicines. Do this test for:
- Patients with Rifampicin resistance reported with GeneXpert
- Also patients on first-line treatment who remain positive at 3 months and are reported Rifampicin sensitive on GeneXpert
- Patients suspected to be failing on first-line treatment
Note: All presumed and diagnosed TB patients should be offered an HIV test